Diasorin’s Luminex subsidiary received FDA 510(k) clearance and CLIA waiver for a multiplex group A streptococcus test on the Liaison Nes point-of-care PCR instrument. The company says the assay produces results in about 15 minutes with less than one minute of hands-on time and includes room-temperature reagent storage. Diasorin positioned the Nes platform as an expandable menu for high-impact infectious diseases, following FDA clearance and CLIA waiver for its respiratory panel for influenza A and B, RSV and COVID-19 in December. At an investor day, the firm outlined plans for the Nes system to reach more than $150 million in U.S. revenue by 2030, and it noted that a gastrointestinal panel on the Liaison Plex system also received FDA clearance in May.